Preserving Prostaglandin E2 Level Prevents Rejection of Implanted Allogeneic Mesenchymal Stem Cells and Restores Postinfarction Ventricular Function | Zendy

Sanjiv Dhingra | Zendy; Peng Li | Zendy; XiPing Huang | Zendy; Jian Guo | Zendy; Jun Wu | Zendy; Anton Mihic | Zendy; Shuhong Li | Zendy; WangFu Zang | Zendy; Daniel H. Y. Shen | Zendy; Richard D. Weisel | Zendy; Pawan K. Singal | Zendy; RenKe Li | Zendy

Open Access

Preserving Prostaglandin E2 Level Prevents Rejection of Implanted Allogeneic Mesenchymal Stem Cells and Restores Postinfarction Ventricular Function

Author(s) -

Sanjiv Dhingra,

Peng Li,

XiPing Huang,

Jian Guo,

Jun Wu,

Anton Mihic,

Shuhong Li,

WangFu Zang,

Daniel H. Y. Shen,

Richard D. Weisel,

Pawan K. Singal,

RenKe Li

Publication year - 2013

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.112.000324

Subject(s) - medicine , mesenchymal stem cell , ventricular function , stem cell , cardiology , prostaglandin e2 , microbiology and biotechnology , pathology , biology

Allogeneic mesenchymal stem cells (MSCs) were immunoprivileged early after cardiac implantation and improved heart function in preclinical and clinical studies. However, long-term preclinical studies demonstrated that allogeneic MSCs lost their immunoprivilege and were rejected in the injured myocardium, resulting in recurrent ventricular dysfunction. This study identifies some of the mechanisms responsible for the immune switch in MSCs and suggests a new treatment to maintain immunoprivilege and preserve heart function.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research